Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
about
Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionThe evolving scenario of non-AIDS-defining cancers: challenges and opportunities of careNew treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy.A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.Pharmacotherapy in cancer patients with HIV/AIDSCancer treatment disparities in HIV-infected individuals in the United States.Current knowledge on HIV-associated Plasmablastic Lymphoma.Noninfectious pulmonary complications of human immunodeficiency virus infectionManagement of HIV infection in patients with cancer receiving chemotherapy.Factors associated with time-to-treatment of prostate cancer in Florida.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.Human immunodeficiency virus-associated lung malignanciesRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.Current questions in HIV-associated lung cancer.Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.HIV-1 and hematopoietic stem cell transplantation.Diagnosis and management of lymphomas and other cancers in HIV-infected patients.Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.Misleading (18)FDG-PET/CT finding caused by chronic HIV infection in a patient with gastric carcinoma: a case report.HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population.Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes?A review of drug-drug interactions in older HIV-infected patients.Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.Malignancies in HIV-Infected and AIDS Patients.Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26749811-2C7D6CAC-B379-4DE9-BA90-48C0296F504CQ26991549-5043EF9E-3DB8-43AC-978F-43CB1EFB5506Q30244166-F9D62327-121D-4C90-BFE1-4A3A94E4507AQ33686288-7F43D95C-4459-478E-BF54-DE3085D28A24Q33881799-E52FCA34-40FF-4DC6-9834-DB53F6BBE5B3Q33927996-3A9BFA60-67D9-4046-8586-41D5E0FB2364Q34531971-4D48330F-3162-4412-8177-294C8695D16CQ34564288-9FA3EE4B-80FA-463B-869C-90AC65F1FE6AQ35008342-28434E96-2704-4BCB-8193-15F06E7FE0FBQ35111947-A0688D9B-203B-4EEE-8832-011DAF64314AQ35848165-52300636-1690-476B-B465-E085CCB4B22FQ35850380-B314D026-E775-43B0-9036-F9346991909BQ36080621-CD985BD6-91F4-4218-96BA-DA7020F7965BQ36243653-C34956FD-ECD1-4611-BDBF-F25E1A02D881Q36818306-D749E380-C3AC-49C3-96AA-E9C4D504FB3BQ36897143-996F97D2-5060-4AB7-9307-1DACE8257496Q37193103-AC126B30-FC64-4A60-9A59-900D2A54E6BAQ37422773-09D8E837-7B62-46C0-BEC2-43132F541C47Q37529316-6E84D4C8-6953-414F-B4EB-D5BF2380AC4AQ37649991-AE7C5931-F8F4-48AC-A46B-F42BF832F05BQ37669678-2EB48DB2-C527-4527-9865-48EACAC3CBFBQ37973860-37F11325-3B06-4552-856E-B6C24EE5050EQ38194845-DD123069-7090-42BF-BD22-96503092C5A2Q38673153-33D42DE2-8A99-413D-9674-AC1A242EF1C8Q38876754-90FB4127-B356-450A-B2FF-4E4E3913E3EEQ39020800-249B192E-4CDF-4352-BE92-C18BA04E7CF2Q40109718-4C5EB293-158E-4551-B586-130ED8679F20Q40284342-8EE333B2-8E1F-4DF3-BA11-247933F272FCQ41930218-00D55963-DE37-4A95-ABAF-292041623517Q41996857-E6F97263-4AC2-41A9-B3B9-8C6456B25EF7Q47255041-76CAFAF8-4F81-47D4-98EC-9EB6D178BB7BQ47886730-76F27722-DA6F-4A60-A13A-FFA00380330EQ48528597-F78269F1-52EA-44A3-9769-A2039BB965BAQ57180790-5A83F414-1229-4CB1-95F2-1C72C07FF38E
P2860
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@ast
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@en
type
label
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@ast
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@en
prefLabel
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@ast
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@en
P2093
P2860
P1433
P1476
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
@en
P2093
Charles Flexner
Michelle A Rudek
Richard F Ambinder
P2860
P304
P356
10.1016/S1470-2045(11)70056-0
P577
2011-05-12T00:00:00Z